Search Results - "Horning, S J"

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma by Hay, A.E., Klimm, B., Chen, B.E., Goergen, H., Shepherd, L.E., Fuchs, M., Gospodarowicz, M.K., Borchmann, P., Connors, J.M., Markova, J., Crump, M., Lohri, A., Winter, J.N., Dörken, B., Pearcey, R.G., Diehl, V., Horning, S.J., Eich, H.T., Engert, A., Meyer, R.M.

“…Treatment options for patients with nonbulky stage IA–IIA Hodgkin lymphoma include combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine…”
Get full text

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience by Hong, F., Habermann, T.M., Gordon, L.I., Hochster, H., Gascoyne, R.D., Morrison, V.A., Fisher, R.I., Bartlett, N.L., Stiff, P.J., Cheson, B.D., Crump, M., Horning, S.J., Kahl, B.S.

“…The role of body mass index (BMI) in survival outcomes is controversial among lymphoma patients. We evaluated the association between BMI at study entry and…”
Get full text

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial by Advani, R.H., Hoppe, R.T., Baer, D., Mason, J., Warnke, R., Allen, J., Daadi, S., Rosenberg, S.A., Horning, S.J.

“…To assess the efficacy of an abbreviated Stanford V regimen in patients with early-stage Hodgkin lymphoma (HL). Patients with untreated nonbulky stage I–IIA…”
Get full text

Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin’s Disease: Mature Results of a Prospective Clinical Trial by Horning, S. J.

Get full text

Follicular lymphoma : Have we made any progress? by HORNING, S. J

“…Follicular lymphomas are characterized by relatively long median survivals and a continuous pattern of relapse. The heterogeneity in these diseases is…”
Get full text

Natural history of and therapy for the indolent non-Hodgkin's lymphomas by Horning, S J

Get more information

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report by Bartlett, N L, Rosenberg, S A, Hoppe, R T, Hancock, S L, Horning, S J

“…Although survival rates have improved for patients with bulky and advanced-stage Hodgkin's disease (HD), current treatments entail substantial acute morbidity…”
Get more information

Long-term survival after histologic transformation of low-grade follicular lymphoma by Yuen, A R, Kamel, O W, Halpern, J, Horning, S J

“…To describe the course of patients following histologic transformation (HT) from low-grade follicular lymphoma to intermediate- or high-grade non-Hodgkin's…”
Get more information

Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease by YUEN, A. R, ROSENBERG, S. A, HOPPE, R. T, HALPERN, J. D, HORNING, S. J

“…Sixty patients with Hodgkin's disease, refractory to or at first recurrence after chemotherapy, received cytoreductive therapy followed by high-dose etoposide,…”
Get full text

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma by Macdonald, D. A., Ding, K., Gospodarowicz, M. K., Wells, W. A., Pearcey, R. G., Connors, J. M., Winter, J. N., Horning, S. J., Djurfeldt, M. S., Shepherd, L. E., Meyer, R. M.

“…Background: In the National Cancer Institute of Canada Clinical Trials Group/Eastern Cooperative Oncology Group HD.6 trial, progression-free survival was…”
Get full text

Introduction: ASCO-ESMO consensus statement on quality cancer care by Horning, S.J., Mellstedt, H.

Get full text

High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory hodgkin's disease : Analysis of the Stanford University results and prognostic indices by HORNING, S. J, CHAO, N. J, NEGRIN, R. S, HOPPE, R. T, LONG, G. D, HU, W. W, WONG, R. M, BROWN, B. W, BLUME, K. G

“…One hundred nineteen patients with relapsed or refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic progenitor…”
Get full text

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial by Stiff, P J, Dahlberg, S, Forman, S J, McCall, A R, Horning, S J, Nademanee, A P, Blume, K G, LeBlanc, M, Fisher, R I

“…To determine the toxicity and prognosis of patients with relapsed and refractory diffuse aggressive non-Hodgkin's lymphoma (NHL) who underwent an autologous…”
Get more information

Response criteria for NHL: Importance of ‘normal’ lymph node size and correlations with response rates by Grillo-López, A. J., Cheson, B. D., Horning, S. J., Peterson, B. A., Carter, W. D., Varns, C. L., Klippenstein, D. L., Shen, C. D.

“…Background: Oncologic literature cites many different definitions of critical response measurements. Patients and methods: Response criteria (RC) for…”
Get full text

Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin’s Disease: Eastern Cooperative Oncology Group Pilot Study E1492 by HORNING, S. J, WILLIAMS, J, BARTLETT, N. L, BENNETT, J. M, HOPPE, R. T, NEUBERG, D, CASSILETH, P

“…This study was performed, in a multi-institutional setting, to evaluate the efficacy and feasibility of the Stanford V chemotherapy regimen plus radiotherapy…”
Get full text

Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation by Horning, S J, Hoppe, R T, Mason, J, Brown, B W, Hancock, S L, Baer, D, Rosenberg, S A

“…We have demonstrated that a relatively mild chemotherapy regimen, vinblastine, methotrexate, and bleomycin (VBM), and involved-field radiotherapy (IFRT) could…”
Get more information

Treatment approaches to the low-grade lymphomas by Horning, S J

Get full text

Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study by Horning, S J, Adhikari, A, Rizk, N, Hoppe, R T, Olshen, R A

“…Because each of very different treatments for Hodgkin's disease (HD) may result in a high rate of cure, attention is currently focused on toxicity. This…”
Get more information

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis by Kwak, L W, Halpern, J, Olshen, R A, Horning, S J

“…While diffuse large-cell lymphoma (DLCL) is considered to be highly curable with current therapy, treatment failures are observed even with intensive…”
Get more information

Granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy by CHAO, N. J, SCHRIBER, J. R, GRIMES, K, LONG, G. D, NEGRIN, R. S, RAIMONDI, C. M, HORNING, S. J, BROWN, S. L, MILLER, L, BLUME, K. G

“…Hematopoietic growth factors have been used to accelerate engraftment after bone marrow transplantation and to "mobilize" peripheral blood progenitor cells…”
Get full text